BRIEF-Personalis Says CMS Revises Reimbursement Rate For Personal Test For Post-Treatment Surveillance Of Cancers

Reuters11-25

BRIEF-<a href="https://laohu8.com/S/PSNL">Personalis</a> Says CMS Revises Reimbursement Rate For Personal Test For Post-Treatment Surveillance Of Cancers

Nov 25 (Reuters) - Personalis Inc PSNL.O:

PERSONALIS INC - CMS REVISES REIMBURSEMENT RATE FOR NEXT PERSONAL TEST FOR POST-TREATMENT SURVEILLANCE OF CANCER - SEC FILING
PERSONALIS INC - EFFECTIVE DECEMBER 1, REIMBURSEMENT RATE FOR NEXT PERSONAL DX BREAST MRD TEST SET AT $4,266 - SEC FILING

Source text: [ID:n0001193125-25-294454]

Further company coverage: PSNL.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2586274854?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-25 19:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2586274854","market":"nz","top_or_hot":-1,"title":"BRIEF-Personalis Says CMS Revises Reimbursement Rate For Personal Test For Post-Treatment Surveillance Of Cancers","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/PSNL\">Personalis</a> Says CMS Revises Reimbursement Rate For Personal Test For Post-Treatment Surveillance Of Cancers</title></head><body><p><span>Nov 25 (Reuters)</span><span> - </span>Personalis Inc <span>PSNL.O</span>:</p><ul><li><p>PERSONALIS INC - CMS REVISES REIMBURSEMENT RATE FOR NEXT PERSONAL TEST FOR POST-TREATMENT SURVEILLANCE OF CANCER - SEC FILING</p></li><li><p>PERSONALIS INC - EFFECTIVE DECEMBER 1, REIMBURSEMENT RATE FOR NEXT PERSONAL DX BREAST MRD TEST SET AT $4,266 - SEC FILING</p></li></ul><p>Source text: [ID:n0001193125-25-294454]</p><p>Further company coverage: <span>PSNL.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Personalis Says CMS Revises Reimbursement Rate For Personal Test For Post-Treatment Surveillance Of Cancers</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Personalis Says CMS Revises Reimbursement Rate For Personal Test For Post-Treatment Surveillance Of Cancers\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-25 19:55</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/PSNL\">Personalis</a> Says CMS Revises Reimbursement Rate For Personal Test For Post-Treatment Surveillance Of Cancers</title></head><body><p><span>Nov 25 (Reuters)</span><span> - </span>Personalis Inc <span>PSNL.O</span>:</p><ul><li><p>PERSONALIS INC - CMS REVISES REIMBURSEMENT RATE FOR NEXT PERSONAL TEST FOR POST-TREATMENT SURVEILLANCE OF CANCER - SEC FILING</p></li><li><p>PERSONALIS INC - EFFECTIVE DECEMBER 1, REIMBURSEMENT RATE FOR NEXT PERSONAL DX BREAST MRD TEST SET AT $4,266 - SEC FILING</p></li></ul><p>Source text: [ID:n0001193125-25-294454]</p><p>Further company coverage: <span>PSNL.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4121","symbol_name":"生命科学工具和服务","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251125:nFWN3X00TX:1","article_id":"2586274854","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2586274854","pubTimestamp":1764071744,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Personalis Says CMS Revises Reimbursement Rate For Personal Test For Post-Treatment Surveillance Of CancersNov 25  - Personalis Inc PSNL.O:PERSONALIS INC - CMS REVISES REIMBURSEMENT RATE FOR NEXT PERSONAL TEST FOR POST-TREATMENT SURVEILLANCE OF CANCER - SEC FILINGPERSONALIS INC - EFFECTIVE DECEMBER 1, REIMBURSEMENT RATE FOR NEXT PERSONAL DX BREAST MRD TEST SET AT $4,266 - SEC FILINGSource text: [ID:n0001193125-25-294454]Further company coverage: PSNL.O ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4121":"生命科学工具和服务","PSNL":"Personalis"},"translate_title":"BRIEF-Personalis表示CMS修改了癌症治疗后监测个人测试的报销率","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PSNL":0.9},"content_text":"BRIEF-Personalis Says CMS Revises Reimbursement Rate For Personal Test For Post-Treatment Surveillance Of CancersNov 25 (Reuters) - Personalis Inc PSNL.O:PERSONALIS INC - CMS REVISES REIMBURSEMENT RATE FOR NEXT PERSONAL TEST FOR POST-TREATMENT SURVEILLANCE OF CANCER - SEC FILINGPERSONALIS INC - EFFECTIVE DECEMBER 1, REIMBURSEMENT RATE FOR NEXT PERSONAL DX BREAST MRD TEST SET AT $4,266 - SEC FILINGSource text: [ID:n0001193125-25-294454]Further company coverage: PSNL.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2586274854","isCrawlerRequest":true}